PMID- 36730111
OWN - NLM
STAT- MEDLINE
DCOM- 20240423
LR  - 20240507
IS  - 1937-1578 (Electronic)
IS  - 1935-1089 (Linking)
VI  - 18
IP  - 3
DP  - 2024 May 1
TI  - TOCILIZUMAB RESOLVES REFRACTORY MACULAR EDEMA ASSOCIATED TO RETINITIS PIGMENTOSA.
PG  - 387-392
LID - 10.1097/ICB.0000000000001389 [doi]
AB  - PURPOSE: The aim of this report is to describe the resolution of refractory 
      cystoid macular edema (CME) associated to retinitis pigmentosa (RP) with IV 
      tocilizumab in three patients. METHODS: Retrospective study of a series of 
      consecutive cases of patients treated with off-label IV tocilizumab (anti IL6) 
      for CME refractory to acetazolamide 250 mg for 3 months. Patients were diagnosed 
      with RP by fundus appearance, electrophysiology, visual fields, and genetic 
      testing. A complete ophthalmic examination including spectral-domain optical 
      coherence tomography was performed. RESULTS: Three patients with RP and CME 
      refractory to acetazolamide 250 mg for 3 months were treated with monthly IV 
      tocilizumab for at least six months.All patients resolved CME and improved visual 
      acuity after the third month of IV tocilizumab, resolving systemic and ocular 
      adverse events related to previous treatments for CME. Tocilizumab was well 
      tolerated with no other adverse events. DISCUSSION: CME causes visual impairment 
      in RP, but current treatments are usually deficient. Tocilizumab has been 
      successfully used as treatment for refractory CME in uveitis, retinal 
      dystrophies, and autoimmune retinopathies. This article reports, for the first 
      time, the long-term resolution of refractory CME in RP with IV tocilizumab.
FAU - Mendez-Martinez, Silvia
AU  - Mendez-Martinez S
AUID- ORCID: 0000-0001-6072-1545
AD  - Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
AD  - Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
AD  - University of Zaragoza, Spain; and.
FAU - Pardinas Baron, Nieves
AU  - Pardinas Baron N
AD  - Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
AD  - Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
AD  - University of Zaragoza, Spain; and.
FAU - Bartol-Puyal, Francisco de Asis
AU  - Bartol-Puyal FA
AD  - Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
AD  - Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
AD  - University of Zaragoza, Spain; and.
FAU - Arias Del Peso, Borja
AU  - Arias Del Peso B
AD  - Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
AD  - Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
AD  - University of Zaragoza, Spain; and.
FAU - Ruiz Del Tiempo, Maria Pilar
AU  - Ruiz Del Tiempo MP
AD  - Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
AD  - Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
AD  - University of Zaragoza, Spain; and.
FAU - Lesta Arnal, Alvaro
AU  - Lesta Arnal A
AD  - Department of Rheumatology, Miguel Servet University Hospital, Zaragoza, Spain.
FAU - Ruiz Moreno, Oscar
AU  - Ruiz Moreno O
AD  - Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
AD  - Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
AD  - University of Zaragoza, Spain; and.
FAU - Manero Ruiz, Javier
AU  - Manero Ruiz J
AD  - University of Zaragoza, Spain; and.
AD  - Department of Rheumatology, Miguel Servet University Hospital, Zaragoza, Spain.
FAU - Pablo Julvez, Luis
AU  - Pablo Julvez L
AD  - Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.
AD  - Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research 
      Institute (IIS Aragon), Zaragoza, Spain.
AD  - University of Zaragoza, Spain; and.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Retin Cases Brief Rep
JT  - Retinal cases & brief reports
JID - 101298744
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - *Antibodies, Monoclonal, Humanized/therapeutic use
MH  - *Macular Edema/drug therapy/etiology
MH  - *Retinitis Pigmentosa/complications
MH  - Retrospective Studies
MH  - *Tomography, Optical Coherence
MH  - *Visual Acuity
MH  - Young Adult
EDAT- 2023/02/03 06:00
MHDA- 2024/04/23 18:51
CRDT- 2023/02/02 13:25
PHST- 2022/09/06 00:00 [received]
PHST- 2022/10/30 00:00 [accepted]
PHST- 2024/04/23 18:51 [medline]
PHST- 2023/02/03 06:00 [pubmed]
PHST- 2023/02/02 13:25 [entrez]
AID - 01271216-990000000-00120 [pii]
AID - 10.1097/ICB.0000000000001389 [doi]
PST - ppublish
SO  - Retin Cases Brief Rep. 2024 May 1;18(3):387-392. doi: 
      10.1097/ICB.0000000000001389.